ReviewGastroenterology2006
Short bowel syndrome: recent clinical outcomes with growth hormone.
Review in Gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.Advanced pharmaceutical bulletin · 2023Article
- GLP-2 Analogues as First Specific Treatment of Intestinal Failure.Visceral medicine · 2019Review
- Hormonal Management of Small Bowel Failure.Clinical and translational gastroenterology · 2017Article
- Management and Complications of Short Bowel Syndrome: an Updated Review.Current gastroenterology reports · 2016Review
- Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.Drugs · 2013Review
- The future developments in nutrition.Frontline gastroenterology · 2012Review
- Short bowel syndrome.Current treatment options in gastroenterology · 2007Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been recent clinical enthusiasm for treating short bowel patients with either human recombinant growth hormone alone or in combination with glutamine and diet in hopes of reducing their parenteral nutrition requirements. Part of this interest has been the result of studies done in short bowel animal models showing increased bowel growth and function following such treatment. Since 1995, 5 key clinical studies have been published in peer-reviewed literature reporting the effects of growth hormone alone or in combination with glutamine and diet in patients with short bowel syndrome. Three of these controlled studies have reported negative results, and 1 controlled and 1 uncontrolled study reported positive results. This review discusses each of these articles and provides some explanation on how these studies and results may have differed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.